BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Analyst Earnings Estimates
NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 170.09% | N/A 72.02% | N/A -25.60% | N/A 49.91% | |||||||||||
| EBITDA YoY % growth | -7.31M | -8.45M -15.60% | -5M 40.83% | -4.91M 1.80% | -13.95M -184.11% | -22.84M -63.73% | -31.46M -37.74% | -24.28M 22.82% | -24.53M -1.03% | -21.174M 13.68% | N/A 32.56% | N/A -7.14% | N/A -53.33% | N/A 26.09% | N/A 494.12% | N/A 174.63% | N/A 66.85% | N/A | N/A | |
| EBIT YoY % growth | -7.42M | -8.54M -15.09% | -5.08M 40.52% | -5M 1.57% | -14.06M -181.20% | -23M -63.58% | -31.68M -37.74% | -24.54M 22.54% | -24.82M -1.14% | -21.439M 13.62% | N/A 37.69% | N/A -86.61% | N/A -11.79% | N/A 2.70% | N/A 185.38% | N/A -48.05% | N/A 452.11% | N/A 152.06% | N/A 61.93% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -6.75 -26.05% | -4.20 37.78% | -4.05 3.57% | N/A -115.33% | -15.90 -82.32% | -16.20 -1.89% | -10.20 37.04% | -9.90 2.94% | N/A -8.18% | N/A 75.67% | N/A 38.94% | N/A 20.83% | N/A 7.69% | N/A 226.75% | N/A 53.98% | N/A 94.16% | N/A -0.23% | N/A 58.70% |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.39 -153.33% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -3.411M 28.99% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.51 -264.29% | -0.59 | 0.08 | 13.04% |
| Q2 2024 Q2Q % growth | -0.60 85.19% | -0.54 | -0.06 | -12.04% |
| Q1 2024 Q2Q % growth | -0.75 64.29% | -1.07 | 0.32 | 29.97% |
| Q4 2023 Q2Q % growth | 92.15% | -0.15 | % | |
| Q3 2023 Q2Q % growth | -0.14 95.09% | -0.14 | 0.00 | 1.96% |
| Q2 2023 Q2Q % growth | -4.05 -42.11% | -2.30 | -1.76 | -76.47% |
| Q1 2023 Q2Q % growth | -2.10 6.67% | -2.52 | 0.42 | 16.82% |
| Q4 2022 Q2Q % growth | -1.95 23.53% | -2.22 | 0.27 | 12.10% |
| Q3 2022 Q2Q % growth | -2.85 -26.67% | -2.75 | -0.10 | -3.49% |
| Q2 2022 Q2Q % growth | -2.85 -11.76% | -2.24 | -0.61 | -27.00% |
| Q1 2022 Q2Q % growth | -2.25 21.05% | -1.99 | -0.26 | -13.12% |
| Q4 2021 Q2Q % growth | -2.55 54.05% | -3.01 | 0.46 | 15.26% |
| Q3 2021 Q2Q % growth | -2.25 -7.14% | -3.14 | 0.89 | 28.26% |
| Q2 2021 Q2Q % growth | -2.55 32.00% | -3.01 | 0.46 | 15.26% |
| Q1 2021 Q2Q % growth | -2.85 40.62% | -3.98 | 1.13 | 28.36% |
| Q4 2020 Q2Q % growth | -5.55 -8.82% | -6.66 | 1.11 | 16.61% |
| Q3 2020 Q2Q % growth | -2.10 44.00% | -3.98 | 1.88 | 47.21% |
| Q2 2020 Q2Q % growth | -3.75 -8.70% | -3.98 | 0.23 | 5.73% |
| Q1 2020 Q2Q % growth | -4.80 -33.33% | -3.44 | -1.36 | -39.43% |
| Q4 2019 Q2Q % growth | -5.10 | -2.70 | -2.40 | -88.68% |
| Q3 2019 Q2Q % growth | -3.75 | -3.37 | -0.38 | -11.41% |
| Q2 2019 Q2Q % growth | -3.45 | -3.67 | 0.22 | 6.05% |
| Q1 2019 Q2Q % growth | -3.60 | -1.15 | -2.45 | -213.73% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2019 Q2Q % growth | 765K | -765K | -100.00% | |
| Q1 2019 Q2Q % growth | 765K | -765K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -4.11% | -4.11% | -3.23% | 0.97% |
| Revenue | N/A | N/A | N/A | N/A |